Alto Neuroscience, Inc. (ANRO)
24.03
+0.51
(+2.17%)
USD |
NYSE |
Oct 08, 16:00
24.02
-0.01
(-0.04%)
Pre-Market: 20:00
Alto Neuroscience Shareholders Equity (Quarterly) : 219.25M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 219.25M |
| March 31, 2026 | 243.37M |
| December 31, 2025 | 151.14M |
| September 30, 2025 | 111.56M |
| June 30, 2025 | 123.41M |
| March 31, 2025 | 139.10M |
| December 31, 2024 | 151.46M |
| September 30, 2024 | 165.05M |
| Date | Value |
|---|---|
| June 30, 2024 | 179.78M |
| March 31, 2024 | 193.10M |
| December 31, 2023 | -71.67M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -38.41M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 254.07M |
| Total Liabilities (Quarterly) | 34.82M |
| Debt to Equity Ratio | 0.1062 |
| Current Ratio | 14.85 |
| Net Debt Paydown Yield | 0.07% |